CNCR - Loncar Cancer Immunotherapy ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.08
-0.15 (-0.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close21.23
Open21.32
Bid0.00 x 900
Ask0.00 x 1000
Day's Range21.08 - 21.22
52 Week Range16.87 - 25.77
Volume3,506
Avg. Volume10,446
Net Assets38.07M
NAV21.22
PE Ratio (TTM)N/A
Yield0.00%
YTD Return11.24%
Beta (3Y Monthly)1.53
Expense Ratio (net)0.79%
Inception Date2015-10-13
Trade prices are not sourced from all markets
  • Cancer-Fighting Stocks & ETF: What You Need to Know
    Zackslast month

    Cancer-Fighting Stocks & ETF: What You Need to Know

    Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

  • Why Cancer-Fighting Stocks & ETFs Are Soaring
    Zackslast month

    Why Cancer-Fighting Stocks & ETFs Are Soaring

    The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

  • These 3 revolutionary genomics companies are changing lives for patients — and investors
    MarketWatch2 months ago

    These 3 revolutionary genomics companies are changing lives for patients — and investors

    While we can research the family tree for these health issues, it’s been difficult to know for sure what could happen — until now. Because of breakthroughs in human genome mapping, we can now get a clear line of sight on what diseases are coming our way — and the insights are only getting better.

  • Morningstar4 months ago

    Don't Fall for a Good Story

    A version of this article was published in the December 2018 issue of Morningstar ETFInvestor. Download a complimentary copy of Morningstar ETFInvestor by visiting the website. Simple, compelling stories tap into our emotions, hijack our ability to think rationally, and persuade us to pursue investments that are unlikely to perform well. The South Sea Company of early 18th century England exemplifies how a well-spun narrative can cause investors to ignore facts and disrupt their ability to make sound investment decisions.

  • Trump Proposes 2020 Budget: ETFs to Top & Flop
    Zacks4 months ago

    Trump Proposes 2020 Budget: ETFs to Top & Flop

    Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.

  • Best and Worst ETFs of Last Week
    Zacks4 months ago

    Best and Worst ETFs of Last Week

    After a solid comeback, the momentum on the Wall Street cooled down last week given the round of dismal data across the globe, the European Central Bank's surprise move and dismal U.S. jobs data that renewed threats of global slowdown.

  • ETF Trends4 months ago

    Healthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain Outlook

    Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit, after FDA Commissioner Scott Gottlieb unexpectedly resigned, ...

  • ETF Trends5 months ago

    Specialized Biotech ETF Rallies on MacroGenics Positive Trial Results

    A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced ...

  • Benzinga11 months ago

    Hone In On Health Care In China With This New ETF

    The Loncar China BioPharma ETF (NASDAQ: CHNA) debuted Wednesday, marking the second ETF from Loncar Investments. CHNA follows the Loncar China BioPharma Index, which was developed by Loncar founder Brad Loncar. “China aims to become a leader in global medicine,” Loncar said in a statement.

  • Business Wire11 months ago

    Loncar China BioPharma ETF (CHNA) Launches on Nasdaq

    Today, the Loncar China BioPharma ETF (Nasdaq:CHNA) begins trading on the Nasdaq in the United States. The CHNA ETF seeks to give investors access to China’s rapidly-developing biopharmaceutical industry. It is based on the Loncar China BioPharma Index, an innovative index developed by biotechnology investor Brad Loncar.

  • Investopedia11 months ago

    Adding Biotech ETFs to Your Portfolio

    As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.

  • 5 Strong Healthcare ETFs to Buy
    InvestorPlace11 months ago

    5 Strong Healthcare ETFs to Buy

    The healthcare sector is the second-largest sector exposure in the S&P 500. This prominence is reflected in the world of exchange-traded funds (ETFs), where there are dozens of healthcare ETFs.